Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gini F Fleming

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Oncology (Williston Park, N.Y.)|June 21, 2013
Management of recurrent EOC: the state of the artGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2007
Systemic chemotherapy for uterine carcinoma: metastatic and adjuvantGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2023
Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical CancerGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2025
Reply to: Reflections on the HORSE Trial: Hyperthermic Intraperitoneal Chemotherapy, <i>BRCA</i> Status, and Clinical ImplicationsGini F Fleming
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
New drugs in ovarian cancerGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Major progress for a less common cancerGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Second-Line Therapy for Endometrial Cancer: The Need for Better OptionsGini F Fleming
Cancer|October 30, 2003
Adjuvant aromatase inhibitors: are we there yet?Gini F Fleming
Oncology (Williston Park, N.Y.)|April 24, 2018
Point: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients. Starting With Reversible OFS Using LHRH Agonists Is Preferred for Most PatientsGini F Fleming, Padma Rajagopal
The Oncologist|July 15, 2016
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsChristine M Bestvina, Gini F Fleming
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Oncology (Williston Park, N.Y.)|June 21, 2013
Management of recurrent EOC: the state of the artGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2007
Systemic chemotherapy for uterine carcinoma: metastatic and adjuvantGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2023
Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical CancerGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2025
Reply to: Reflections on the HORSE Trial: Hyperthermic Intraperitoneal Chemotherapy, <i>BRCA</i> Status, and Clinical ImplicationsGini F Fleming
Clinical Advances in Hematology & Oncology : H&O|September 10, 2015
New drugs in ovarian cancerGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Major progress for a less common cancerGini F Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Second-Line Therapy for Endometrial Cancer: The Need for Better OptionsGini F Fleming
Cancer|October 30, 2003
Adjuvant aromatase inhibitors: are we there yet?Gini F Fleming
Oncology (Williston Park, N.Y.)|April 24, 2018
Point: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients. Starting With Reversible OFS Using LHRH Agonists Is Preferred for Most PatientsGini F Fleming, Padma Rajagopal
The Oncologist|July 15, 2016
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsChristine M Bestvina, Gini F Fleming
Pageof 18